News & Updates

Show Multimedia Only

Initial vision, infiltrate size predict outcomes in microbial keratitis

Several factors contribute to the risk for worse 90-day best-corrected visual acuity (BCVA) in patients with microbial keratitis (MK), and these include initial vision, longer time until presentation, and larger infiltrate size, reports a study.

Initial vision, infiltrate size predict outcomes in microbial keratitis

a day ago

Nonproliferative may progress to proliferative DR after cataract surgery

14 Jul 2025

Patients with type 2 diabetes (T2D) and nonproliferative diabetic retinopathy (NPDR) who undergo modern cataract surgery tend to progress to proliferative diabetic retinopathy (PDR) within a year after the procedure, reveals a recent study.

Nonproliferative may progress to proliferative DR after cataract surgery

14 Jul 2025

Is cannabis protective against proliferative vitreoretinopathy after retinal detachment repair?

07 Jul 2025

Cannabis users who underwent initial repair for retinal detachment (RD) appear to be at lower risk of developing proliferative vitreoretinopathy and, in turn, requiring subsequent complex RD repair when compared with their nonuser peers, according to a retrospective study.

Is cannabis protective against proliferative vitreoretinopathy after retinal detachment repair?

07 Jul 2025

A turning point in nAMD treatment with high-dose aflibercept formulation

24 Jun 2025 by

Increasing experience among ophthalmologists and patients attests to the durable efficacy and safety of the 8 mg formulation of the anti–vascular endothelial growth factor (anti-VEGF), aflibercept, in the treatment of neovascular age-related macular degeneration (nAMD). At an industrysponsored meeting, Dr Kenneth Fan of the Retina Consultants of Texas in Houston, Texas, US, reaffirmed the benefits of high-dose aflibercept in nAMD, highlighting how the positive experiences of his patients align with results of the pivotal PULSAR trial.

A turning point in nAMD treatment with high-dose aflibercept formulation

24 Jun 2025

HDL levels linked to AMD risk

10 Jun 2025

Both high and low levels of high-density lipoprotein (HDL) are significantly associated with an elevated risk of age-related macular degeneration (AMD), reveals a study.

HDL levels linked to AMD risk

10 Jun 2025

Eye diseases prevalent among CKD patients in SG

06 Jun 2025 by

Patients with chronic kidney disease (CKD) have a particularly high burden of eye diseases, including diabetic retinopathy (DR) and age-related macular degeneration (AMD), despite receiving regular medical follow-up, as shown in a study from Singapore.

Eye diseases prevalent among CKD patients in SG

06 Jun 2025

Faricimab outclasses aflibercept in treatment of nAMD

11 May 2025

In adult patients with treatment-naive neovascular age-related macular degeneration (nAMD), the use of faricimab shows superior anatomic outcome compared with aflibercept during the head-to-head dosing phase, reports a study.

Faricimab outclasses aflibercept in treatment of nAMD

11 May 2025

Dexamethasone trumps MTX, ranibizumab in treatment of macular oedema

10 May 2025

A recent study has found that dexamethasone delivers better outcomes than methotrexate (MTX) and ranibizumab in patients with persistent or recurrent uveitic macular oedema through 24 weeks. In addition, side effects are manageable.

Dexamethasone trumps MTX, ranibizumab in treatment of macular oedema

10 May 2025

Durable vision outcomes and extended Tx interval with aflibercept 8 mg in nAMD and DME: Insights for clinical practice

23 Apr 2025 by

Anti-vascular endothelial growth factor (anti-VEGF) agents are considered the standard of care (SoC) for neovascular agerelated macular degeneration (nAMD) and diabetic macular oedema (DME). However, the need for frequent intravitreal (IVT) injections leads to a substantial treatment burden. In an interview with MIMS Doctor, Professor Michael Stewart of the Mayo Clinic in Jacksonville, Florida, US, discussed how the highdose formulation of the anti-VEGF agent, aflibercept 8 mg, may address challenges associated with nAMD and DME management based on results of the pivotal PULSAR and PHOTON trials as well as his patients’ early experience.

Durable vision outcomes and extended Tx interval with aflibercept 8 mg in nAMD and DME: Insights for clinical practice

23 Apr 2025

Gradual adalimumab tapering minimizes uveitis recurrence in children

15 Apr 2025

In children with noninfectious uveitis being treated with adalimumab, tapering speed appears to affect the risk of relapse, with a slow, gradual approach emerging as the optimal strategy, according to a multicentre retrospective cohort study.

Gradual adalimumab tapering minimizes uveitis recurrence in children

15 Apr 2025

News & Updates

Filter by Specialty:

Specialty:

Initial vision, infiltrate size predict outcomes in microbial keratitis

Initial vision, infiltrate size predict outcomes in microbial keratitis

Nonproliferative may progress to proliferative DR after cataract surgery

Nonproliferative may progress to proliferative DR after cataract surgery

Is cannabis protective against proliferative vitreoretinopathy after retinal detachment repair?

Is cannabis protective against proliferative vitreoretinopathy after retinal detachment repair?

A turning point in nAMD treatment with high-dose aflibercept formulation

A turning point in nAMD treatment with high-dose aflibercept formulation

HDL levels linked to AMD risk

HDL levels linked to AMD risk

Eye diseases prevalent among CKD patients in SG

Eye diseases prevalent among CKD patients in SG

Faricimab outclasses aflibercept in treatment of nAMD

Faricimab outclasses aflibercept in treatment of nAMD

Dexamethasone trumps MTX, ranibizumab in treatment of macular oedema

Dexamethasone trumps MTX, ranibizumab in treatment of macular oedema

Durable vision outcomes and extended Tx interval with aflibercept 8 mg in nAMD and DME: Insights for clinical practice

Durable vision outcomes and extended Tx interval with aflibercept 8 mg in nAMD and DME: Insights for clinical practice

Gradual adalimumab tapering minimizes uveitis recurrence in children

Gradual adalimumab tapering minimizes uveitis recurrence in children